The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.

The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.

The present disclosure relates to nanoparticle compositions for use as vaccines against Clostridium perfringens in poultry which causes necrotic enteritis in poultry. Such compositions include one or more Clostridium perfringens extracellular proteins entrapped in a polyanhydride or chitosan nanoparticle. The one or more Clostridium perfringens extracellular proteins may include one or more Clostridium perfringens toxins, such as, for example, alpha toxin (CPA), beta toxin (CPB), epsilon toxin (ETX), iota toxin (ITX), perfringolysin O (PFO), enterotoxin (CPE), beta2 toxin (CPB2), or NetB toxin. In some aspects, the composition further includes a Salmonella enteritidis flagellar protein. The present invention also includes methods for the oral delivery of one or more Clostridium perfringens extracellular proteins to the mucosal membrane of the intestinal tract of a bird of the order Galliformes.

The present disclosure relates to nanoparticle compositions for use as vaccines against Clostridium perfringens in poultry which causes necrotic enteritis in poultry. Such compositions include one or more Clostridium perfringens extracellular proteins entrapped in a polyanhydride or chitosan nanoparticle. The one or more Clostridium perfringens extracellular proteins may include one or more Clostridium perfringens toxins, such as, for example, alpha toxin (CPA), beta toxin (CPB), epsilon toxin (ETX), iota toxin (ITX), perfringolysin O (PFO), enterotoxin (CPE), beta2 toxin (CPB2), or NetB toxin. In some aspects, the composition further includes a Salmonella enteritidis flagellar protein. The present invention also includes methods for the oral delivery of one or more Clostridium perfringens extracellular proteins to the mucosal membrane of the intestinal tract of a bird of the order Galliformes.

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

The embodiments relate to improved skin quality, health and appearance using a new delivery method and certain bioactive compositions and formulations. The system incorporates microneedle delivery technology with unique compositions and formulations. Such development allows for the pursuit of personalized medicine, or treatment delivery that can expand to remote controlled environment, immediate compounding and ultimate personalization with a state of the art longitudinal data predictive analytics. Certain formulations described herein are unique, combinatory and synergistic. Secured by high-tech proprietary system, there are unlimited potentials using AQT technology including but not limited to 3-D printing of a biodegradable micro chips that can be delivered via injection, AQT or any other possible route.

The embodiments relate to improved skin quality, health and appearance using a new delivery method and certain bioactive compositions and formulations. The system incorporates microneedle delivery technology with unique compositions and formulations. Such development allows for the pursuit of personalized medicine, or treatment delivery that can expand to remote controlled environment, immediate compounding and ultimate personalization with a state of the art longitudinal data predictive analytics. Certain formulations described herein are unique, combinatory and synergistic. Secured by high-tech proprietary system, there are unlimited potentials using AQT technology including but not limited to 3-D printing of a biodegradable micro chips that can be delivered via injection, AQT or any other possible route.

A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one hydrophobic domain and where the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.

A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one hydrophobic domain and where the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.